@article{dce5fc2ed34944bd93628074fb7348f8,
title = "Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up",
keywords = "cemiplimab, clinical trial, hedgehog inhibitor, immune checkpoint inhibitor, locally advanced basal cell carcinoma, phase 2, quality of life",
author = "Stratigos, {Alexander J.} and Aleksandar Sekulic and Ketty Peris and Oliver Bechter and Sorilla Prey and Lewis, {Karl D.} and Nicole Basset-Seguin and Chang, {Anne Lynn S.} and St{\'e}phane Dalle and {Fern{\'a}ndez Orland}, Almudena and Lisa Licitra and Caroline Robert and Claas Ulrich and Axel Hauschild and Migden, {Michael R.} and Reinhard Dummer and Yoo, {Suk Young} and Emmanuel Okoye and Ioannis Bassukas and Carmen Loquai and {De Giorgi}, Vincenzo and Zeynep Eroglu and Ralf Gutzmer and Jens Ulrich and Susana Puig and Inocencio, {Timothy J.} and Chen, {Chieh I.} and LaFontaine, {Patrick R.} and Frank Seebach and Israel Lowy and Fury, {Matthew G.}",
year = "2024",
month = feb,
doi = "10.1016/j.jaad.2023.08.111",
language = "English (US)",
volume = "90",
pages = "414--418",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",
}